Pan-Biome Pharmaceuticals, Inc. provides an update on its
VANCOUVER, British Columbia, 02 Dec. 2021 (GLOBE NEWSWIRE) – Pan-Biome Pharmaceuticals, Inc., a Vancouver-based preclinical biopharmaceutical company specializing in chronic inflammatory and autoimmune diseases, studies whether its small-molecule, naturally-occurring compounds in products can prolong life duration and longevity of human health by slowing the onset of age-related diseases, thereby enabling people to live longer and healthier lives. In a 2019 note to its investors, Bank of America Merrill Lynch suggested that “human longevity could be the biggest and disruptive opportunity of our time,” predicting a market opportunity that could reach US $ 610 billion by now. 2025.
Pan-Biome CSO Dr Poul Sorensen: âDespite the obvious link between aging, inflammation and chronic disease, research dollars continue to be spent fighting these diseases one by one. We believe that there are common mechanisms linking age-related diseases, and we intend to demonstrate the effectiveness of our multi-target therapies on a range of these diseases.
In a recent study using a well-established longevity model, the nematode Caenorhabditis elegans (C. elegans) worm, Pan-Biome compounds dramatically increased the lifespan of worms by up to 30%. C. elegans shares many of its major metabolic pathways with those of humans, and many key genetic players that influence worm lifespan have done the same in humans.
Pan-Biome compounds exhibit a wide variety of effects on immune and inflammatory responses, targeting cytokine pathways such as IL-1b, IL-6, IL-8, IL-13, IL-17A, IL-17E and IL- 31, which are overexpressed in many important diseases. Studies suggest that targeting chronic low-grade inflammation (inflammation) or the mechanisms that cause it may slow aging and its associated diseases.
In a mouse model study conducted earlier this year, Pan-Biome’s orally administered compound produced a potent effect on modulating the gut microbiome, significantly affecting several important bacteria such as Akkermansia muciniphila and Firmicutes. As we age, the immune system and the gut microbiome undergo significant changes in their makeup and function. New studies suggest that targeting age-related changes in the composition of the gut microbiota may improve health and lifespan, in part by reducing low-grade systemic inflammation and altering immune functions, two hallmarks of the gut. aging process.
Pan-Biome compounds also exhibit broad antibacterial activities against oral pathogens P. gingivalis and F. core, bacteria linked to the development of a number of age-related diseases, including rheumatoid arthritis, Alzheimer’s disease, cancer and respiratory diseases.
Our compounds strongly induce the expression of NRF2, a major antioxidant cytoprotective signaling pathway that regulates a battery of over 350 cellular stress defense genes with roles in stress resistance, and with a potential direct link to longevity. and the lifespan. The loss of the activation of NRF2 could allow oxidative stress to not be attenuated and to drive the aging process.
Pan-Biome CEO Gordon Eberwein: âIt’s less about the length of our life than the length of our health. We believe that our compounds can fight the aging process by targeting pathways and mechanisms that can slow aging and the onset of age-related diseases, allowing us to live healthier longer lives.
About Pan-Biome Pharmaceuticals, Inc.
Pan-Biome Pharmaceuticals, Inc. is a preclinical biopharmaceutical company offering a line of naturally occurring compounds dedicated to healthy aging and the progression of drugs that can treat and potentially slow the onset of many age-related diseases. . Our compounds are well tolerated and exhibit new anti-inflammatory, antimicrobial, antioxidant and anticancer properties.
Investor Inquiries: Gordon Eberwein